This page is updated frequently with new Receptor-related patent applications.
|Current diverter ring|
The current diverter rings and bearing isolators serve to dissipate an electrical charge from a rotating piece of equipment to ground, such as from a motor shaft to a motor housing. One embodiment of the current diverter ring includes an inner body and an outer body configured to clamp at least one conductive segment between them.
|Image forming apparatus and installation or removal of housing including photoreceptors|
Provided is an image forming apparatus including plural developing devices that are provided side by side in a direction that is defined by an image forming apparatus main body and respectively form insertion sections into or from which housings including photoreceptors are inserted or withdrawn in a longitudinal direction on one side in a direction in which the plural developing devices are arranged, an exit mechanism that is provided in the developing device, is disposed on an inlet side of the insertion section, and exits a developer on an inside of the developing device, and guide sections of at least two portions that are provided in at least one of the developing devices adjacent to the housing and guide the housing before a surface of the photoreceptor faces the exit mechanism in an insertion direction of the housing when the housing is inserted or withdrawn.. .
Fuji Xerox Co., Ltd.
|Image forming apparatus|
An image forming apparatus comprises a developing unit and a developing unit attaching portion that is provided in an apparatus main body. The developing unit and the developing unit attaching portion are provided with an insertion guide.
Sharp Kabushiki Kaisha
|Fluorinated structured organic film photoreceptor layers|
A method of forming an overcoat layer. The method comprises providing a substrate having an imaging structure formed thereon, the imaging structure comprising (i) a charge transport layer and a charge generating layer, or (ii) an imaging layer comprising both charge generating material and charge transport material.
|Polycarbonate copolymer, coating solution, electrophotographic photoreceptor, and electric device|
In the above formula (1), r1 is a hydrogen atom or an alkyl group having 1 to 2 carbon atoms; an average repeating number n is in a range from 6 to 40 and l is an integer of 1 to 4; and when an aromatic ring is substituted by two or more of r1 (l≧2), the two or more of r1 are the same or different from each other.. .
|Electrophotographic photoreceptor, image forming apparatus using the same, and image forming method|
An electrophotographic photoreceptor for use in an image forming apparatus having a proximity charge-type charging unit includes a conductive support and at least photosensitive layer and surface layer laminated in order on the conductive support, wherein the surface layer includes (a) a charge transport material, (b) a cured product of a composition containing a polymerizable compound and inorganic fine particles, and (c) organic fine particles, and the inorganic fine particles contain a metal oxide, has a surface treated with a surface treatment agent having a reactive organic group, and has a volume resistivity of 1.2×1011 Ω·cm or more.. .
Konica Minolta, Inc.
|Systems and methods for treating patients having a genetic predisposition to develop prostate cancer|
Systems and methods for mitigating prostate cancer development are provided. Peripheral blood cells may be evaluated for the presence or quantity of gamma-h2ax foci, and/or for gene alterations encoding a protein with impaired or lack of function, for example, because the encoded protein is truncated, and correlating with prostate cancer development.
Institute For Cancer Research D/b/a The Research Institute Of Fox Chase Cancer Center
|Modulators of growth hormone receptor|
The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (ghr).. .
Ionis Pharmaceuticals, Inc.
|Melk regulation for the treatment of breast cancer|
Methods for inhibiting growth or proliferation of breast cancer cells are provided. The methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a melk inhibitor, wherein the breast cancer cells are estrogen receptor (er) negative.
|Compositions and methods for selective delivery of oligonucleotide molecules to cell types|
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes..
Nlife Therapeutics, S.l.
Treatment for conditions associated with fibrosis and collagen deposition
Methods, compositions, devices, and kits for treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition are provided. The method of treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition in a subject includes administering an effective amount a mirna-762 inhibitor to the subject, wherein the subject is identified as having a risk of developing and/or a need for treatment of the condition associated with fibrosis and/or collagen deposition.
Antibodies against the ectodomain of erbb3 and uses thereof
The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of erbb3 receptor and inhibit various erbb3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated erbb3 and inhibiting egf-like ligand mediated phosphorylation of the receptor.
Merrimack Pharmaceuticals, Inc.
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (fra) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to fra-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors.
Method of engineering multi-input signal sensitive t cell for immunotherapy
The present invention relates to a method to engineer immune cell for immunotherapy. In particular said immune cells are engineered with chimeric antigen receptors, which be activated by the combination of hypoxia and ligand extracellular binding as input signals.
Anti-kit antibodies and uses thereof
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human kit antigen comprising the fourth and/or fifth extracellular ig-like domains (that is, d4 and/or d5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit kit activity, such as ligand-induced receptor phosphorylation.
Kolltan Pharmaceuticals, Inc.
The present invention concerns human antibodies recognising the human c5a receptor. By binding to c5ar the antibodies inhibit c5a signalling, whereby the pro-inflammatory signal is inhibited.
Novo Nordisk A/s
Egfr targeted therapy of neurological disorders and pain
The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to the epidermal growth factor receptor (egfr) as a clinical target for treatment of neurological disorders, preferably in conjunction with neuropathic pain.
Sykehuset Sørlandet Hf
Methods of treating kawasaki disease using il-1b antibodies
This invention relates to a novel use of il-1β-ligand/il-1 receptor disrupting compounds (herein referred to as “il-1 beta compounds”); such as small molecular compounds disrupting il-1b ligand-il-1 receptor interaction, il-1b antibodies or il-1 receptor antibodies, e.g. Il-1b binding molecules described herein, e.g.
Gitrl fusion proteins and uses thereof
The disclosure provides gitrl fusion polypeptide subunits comprising an igg fc domain, a trimerization domain, and the receptor binding domain of gitr ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer..
A chimeric peptide that interacts with cell membrane gangliosides
The invention relates to a chimeric peptide displaying the ganglioside-binding properties of both α-synuclein and β-amyloid peptide. Such peptide is useful in preventing or treating any condition which involves gangliosides as cell surface receptor sites, including neurodegenerative disorders, infectious diseases, or tumors..
Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use
And pharmaceutically acceptable salts thereof, wherein r1, r2 and r3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid b (gaba-b) receptor. Methods for making the compounds are described.
Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, formula (i) wherein l, x, ra, rb, r1, r2 and r3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.. .
Takeda Pharmaceutical Company Limited
Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
This invention relates to a novel crystalline form of 6-[(4r)-4-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile which is useful as a selective androgen receptor modulator (sarm), and to compositions thereof and suitable processes for the preparation thereof.. .
Multivalent ligands targeting vegfr
Compounds that target vascular endothelial growth factor receptors for therapy and imaging are disclosed. Methods for making the compounds and detecting or imaging cells expressing vegfr using the compounds are also provided.
The Methodist Hospital System
Benzomorphan analogs and use thereof
The invention provides compounds as represented by formula i or i′ and pharmaceutically acceptable salts, solvates, and diastereomers thereof: wherein r1, r2, r2a, r3, and r4 are defined in the disclosure. The invention also provides compounds of formulae ii, iii, and a-h, and pharmaceutically acceptable salts, solvates, and diastereomers thereof.
Purdue Pharma L.p.
This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.. .
Glaxosmithkline Intellectual Property (no. 2) Limited
Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.
Photothermal nanostructures in tumor therapy
Methods, structures, devices and systems are disclosed for implementing a photothermal therapy using nanostructures. In one aspect, a device to produce a photothermal effect includes a particle having a molecular layer functionalized onto the external surface of the particle and structured to attach to one or more targeting molecules capable of binding to a receptor site of a cell, in which the particle is configured to absorb light energy at a particular wavelength to produce a plasmon resonance effect that causes the particle to emit heat energy.
Toll-like receptor 2 agonists and vaccines and uses thereof
The present invention relates to toll-like receptor 2 (tlr2) agonists, in particular, to tlr2-activating lipoproteins, and more particularly to tlr2-activating lipopeptides derived from the bacteria bordetella pertussis. The invention further extends to the use of said tlr2-activating lipoproteins as a therapeutic or as part of a vaccine composition in the treatment and prevention of infectious diseases, cancer or allergic diseases..
The Provost, Fellows, Foundation Scholars & The Other Members Of Board, Of The College Of The Holy
Prenatal therapy to induce immune tolerance
Constructs and methods for inducing immune tolerance during gestation, e.g. In utero, are provided.
Inserm (institut National De La Santé Et De La Recherche Médicale)
Targeted mutant alpha-helical bundle cytokines
This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells.
Combination therapy for the treatment of cancer
Described are methods and compositions for treating cancer that include a dopamine receptor (dr) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a dna synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel.
Methods for inhibiting cellular uptake of the anthrax lethal toxin (lt) protein complex
The present invention identifies compounds that disrupt the interaction between anthrax proteins and lrp5/6 receptors, resulting in a reduction in anthrax toxicity. The compounds act to disrupt the intracellular transport of toxin complexes into a target cell.
Enzo Biochem, Inc.
Combination treatment of specific forms of epilepsy
Formulations for and methods of treatment of dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-ht receptor agonists which does not agonize selected 5-ht receptor subtypes, and in particular does not agonize the receptor subtype 5-ht2b.
Zogenix International Limited
Modulators of toll-like receptors for the treatment of hiv
Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of tlr8 and pharmaceutically acceptable salts thereof, useful in treating hiv infections.. .
Gilead Sciences, Inc.
Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (tki), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic form of a tki to another polymorphic form and/or an amorphous form..
Forsight Vision4, Inc.
Wherein l, r, r3, r4, r5, r6, r7, x1, x2, x3, x4, y, m and n have the meaning according to the claims, are positive allosteric modulators of the fsh receptor, and can be employed, inter alia, for the treatment of fertility disorders.. .
Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b
Compounds that selectively negatively modulate nmda receptors containing an nr1/nr2b subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.. .
Luc Therapeutics, Inc.
Prototypical analgesic profile of 3,3-diphenyl-n-(1-phenylethyl)propan-1-amine (fendiline)
The present invention discloses the prototypical profile of 3,3-diphenyl-n-(1-phenylethyl) propan-1-amine (fendiline) against the anticancer drugs induced neuropathic pain (adinp). Indeed, fendiline exhibited high analgesic activity against the paclitaxel induced neuropathic sensitization (pins), in mice, and also inducing decrease of brain dopamine (da) turnover, in rats and mice, i.e., the exactly opposite effects of those induced by the μ-opioid receptor agonists (μ-oras).
Nicotinic receptor non-competitive antagonists
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.. .
Catalyst Biosciences, Inc.
Pharmaceutical composition for the treatment of dry eye
The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a trpm8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a trpm8 receptor antagonist..
Consejo Superior De Investigaciones CientÍficas C.s.l.c.
Nasal drug products and methods of their use
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided..
Methods useful for vitamin d deficiency and related disorders
Methods for diagnosing, treating, and preventing catabolism-related vitamin d deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring cyp24 expression and/or activity, or a proxy thereof such as fgf23 level, in a patient and correlating abnormally elevated cyp24 expression and/or activity with catabolism-related vitamin d deficiency or with susceptibility for catabolism-related vitamin d deficiency.
Opko Ireland Global Holdings, Ltd.
Method and device for detection of pseudomonas aeruginosa
A method of and device for detecting and diagnosing pseudomonal aeruginosa in a gaseous, liquid or solid sample, employing lux-r-like receptor-driven reporter cells.. .
Yeda Research And Development Co. Ltd.
Use of inhibitors of leukotriene b4 receptor blt2 for treating asthma
The present invention relates to the use of inhibitors of leukotriene b4 receptor blt2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising blt2 inhibitors and a method for treating asthma using blt2 inhibitors..
Korea University Research & Business Foundation
Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays
The following discloses mammalian cells lines that stably express functional nematode acetylcholine receptor subunits. The resulting expression of functional ion channels has been made possible by the stable co-expression of the chaperone protein, ric3.
A system and method for an electrochemical detector includes a plurality of receptors disposed on a semiconductor layer, wherein the plurality of receptors are arranged to interact with a target substance so as to alter an electrical characteristic of the semiconductor layer.. .
City University Of Hong Kong
Novel mutation in the epidermal growth factor receptor kinase domain
A new in-frame deletion was found in exon 19 of the egfr gene, the exon that is often mutated in tumors. The invention comprises methods of detecting the mutation, methods of prognosis and methods of predicting response to treatment based on the presence of absence of the mutation..
Roche Molecular Systems, Inc.
Microrna treatment of fibrosis
Provided herein are micrornas that target transforming growth factor beta (tgf-β) receptors and attenuate pathways of fibrosis. In particular, microrna-1343 reduces expression of tgfbr1 and tgfbr2, decreases tgf-β signaling, represses pathways of fibrosis, and treats fibrotic diseases..
Method for in situ inhibition of regulatory t cells
The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are designed to express both a chimeric antigen receptor (car) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory t-cells (treg).
A producing an adult-type oligodendrocyte
The present invention provides a method for producing adult oligodendrocyte progenitor cells from proliferative oligodendrocyte progenitor cells, and a pharmaceutical composition having for an active ingredient thereof adult opc produced according to that method. The method for producing adult opc of the present invention is characterized by inducing proliferating opc to differentiate into adult opc by culturing in the presence of a ligand of a thyroid hormone receptor or retinoic acid receptor in a low oxygen environment.
Japan Science And Technology Agency